Paragonix Technologies aims to boost survival of donated lungs
Image courtesy of Paragonix Technologies Many lungs being transported for transplant arrive in such bad shape that they cannot be used. Paragonix Technologies, Inc. aims to change that with SherpaLung, a specialized cooler that keeps lungs properly inflated and at the right temperature to survive an airplane trip. Paragonix Technologies just landed support from the Lung Transplant Foundation to continue developing and commercialize SherpaLung, the latest in its series of specialized organ transport carriers. Braintree, MA-based Paragonix launched similar devices for hearts and kidneys within the past several months, according to CEO Bill Edelman. Get the full story on our sister site, Medical Design &Outsourcing The post Paragonix Technologies aims to boost survival of donated lungs appeared first on MassDevice.
This study provides a possible reason why genes carrying health risks have persisted in human populations. The second found evidence for multiple variants in genes related to ageing that exhibited antagonistic pleiotropic effects. They found higher risk allele frequencies with large effect sizes for late-onset diseases (relative to early-onset diseases) and an excess of variants with antagonistic effects expressed through early and late life diseases. There also exists other recent tangible evidence of antagonistic pleiotropy in specific human genes. The SPATA31 gene has been found under strong positive genomic sele...
In the setting of Cardiogenic Shock (CS), impaired biventricular function can lead to an acute decrease in renal function via reduced renal perfusion and increased renal venous pressure. In a nationally representative sample, we sought to analyze the characteristics and outcomes of patients hospitalized with CS requiring renal replacement therapy (hemodialysis) for acute kidney injury (AKI-HD).
We examined the relative importance of ABMR vs TCMR in heart transplant endomyocardial biopsies (EMBs), and the molecules predicting graft survival.
The study aim was to investigate exposure to mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), after pediatric orthotopic heart transplantation (pOHT). Previous studies in pediatric kidney recipients demonstrated a relationship between MPA concentration and risk of rejection or hematologic side effects. The quantification of MPA in pOHT is not well established, and the relationship between a single-time-point-correlate and area under the curve (AUC) is lacking. We sought to assess the clinical individualization of MPA dosing after initiation of MPA AUC measurements in our patients.
TBB histologic assessment of CLAD status, particularly late post-LTx, is typically clinically unhelpful. Microarray analyses using the Molecular Microscope Diagnostic System (MMDx) in kidney&heart recipients are proving useful in providing mechanistic targets that inform therapeutic interventions, and could show similar promise in LTx.
To analyze post-heart transplantation (HTx) outcomes in selected patients on ECMO support. Our local strategy is to transplant ECMO-patients without mechanical ventilation or kidney failure (creatinine clearance ≤ 30 mL/min or dialysis). In addition, specific pre-transplant (intra-aortic balloon pump, reperfusion canula) and post-transplant strategies (maintaining ECMO after HTx) were applied.
To describe long-term changes in kidney function after left ventricular assist device (LVAD) implant.
Ongoing opioid epidemic has led to an increase in hepatitis C virus (HCV)+ organs. Given excellent cure rates with direct acting antivirals (DAAs), there is interest in using such organs for transplant.
We examined outcomes of pediatric sHKTx compared to pediatric heart transplant alone (PHTx). Our objective was to identify a threshold estimated glomerular filtration rate (eGFR) that justified pediatric sHKTx.
This study analysed its impact on the mortality and long-term renal function in adult cardiac recipients in the UK.